Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 26Urinary Bladder Neoplasms 23Ureteral Neoplasms 8Urologic Neoplasms 4Urethral Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Neoplasm Metastasis 3Urogenital Neoplasms 2Peripheral Nervous System Diseases 2Muscle Invasive Bladder Urothelial Carcinoma 2Metastatic Urothelial Cancer 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Bladder Cancer 2Urothelial Cancer 1Urologic Diseases 1Urogenital Diseases 1Urinary Bladder Diseases 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Pancreatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Muscle-invasive Bladder Cancer 1

Interventions

Drug Therapy 2tremelimumab 1pembrolizumab 1enfortumab vedotin 1durvalumab 1atezolizumab 1Watchful Waiting 1Radiotherapy 1Palliative Care 1Magnetic Resonance Spectroscopy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscle-invasive Bladder Cancer × enfortumab vedotin × Clear all
NCT07475806 2026-06-05

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Astellas Pharma Inc

Phase 2 Recruiting
240 enrolled
Genitourinary

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡